Models of cervical screening in the era of human papillomavirus vaccination

Sexual Health

Volumn 7, Issue 3, 2010, Pages 359-367

  Canfell, Karen ^a,b  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Australia; Pap smear; simulation modelling

Indexed keywords

WART VIRUS VACCINE;

AUSTRALIA; AUTOMATED IMAGE READ OF LBC; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; CROSS REACTION; DNA VIRUS INFECTION; DRUG EFFECT; ECONOMIC EVALUATION; FEMALE GENITAL TRACT CYTOLOGY; HEALTH CARE POLICY; HUMAN; INFECTION RATE; INFECTION RISK; LIQUID BASED CYTOLOGY; MASS SCREENING; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SIMULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AUSTRALIA; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MASS SCREENING; MASS VACCINATION; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGRAM EVALUATION; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77956046993     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH10016     Document Type: Review

References (57)

1. Australian Institute of Health and Welfare. Cervical Screening in Australia 2006-2007. Report No.: Cat. No. CAN 43. Canberra: Australian Institute of Health and Welfare; 2009.
2. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust 2006; 185: 482-486
3. National Health and Medical Research Council. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra: NHMRC; 2005. Available online at: synopses/wh39syn.htm [verified July 2010].
4. International Agency for Research on Cancer. GLOBOCAN 2002. Lyon: IARC; 2005. Available online at: [verified July 2010].
5. Curado MP, Edwards B, Shin HR, Storm H, Frelay J, Heanue M, et al. Cancer incidence in five continents, Vol.IX. Report No.: IARC Scientific Publications No. 160. Lyon: IARC; 2007.
6. International Agency for Research on Cancer. WHO mortality database extracted from the World Health Organization (WHO) Databank. Lyon: IARC; 2005. Available online at: . iarc.fr/ [verified July 2010].
7. Neville AM, Quinn MA. An alternative cost effectiveness analysis of ThinPrep in the Australian setting. Aust N Z J Obstet Gynaecol 2005; 45: 289-294 doi:10.1111/j.1479-828X.2005.00413.x (Pubitemid 41122590)
8. Anderson R, Haas M, Shanahan M. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range? Aust N Z J Public Health 2008; 32: 43-52. doi:10.1111/j.1753-6405.2008.00165.x (Pubitemid 351351020)
9. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007; 4: 165-175 doi:10.1071/ SH07043
10. Medical Services Advisory Committee. Automation assisted and liquid based cytology for cervical cancer screening. MSAC reference 1122, Assessment report. Canberra: MSAC; 2009. Available online at: 2AD0E9BD12315EB9CA2575C5002872A9/ $File/1122-MSAC- Assessment-Report.pdf [verified July 2010].
11. Medical Services Advisory Committee. Human papillomavirus triage test for women with possible or definite low-grade squamous intraepithelial lesions. Canberra: MSAC; 2009. Available online at: D98FE64C8A2FCA2575AD0082FD8F/ $File/39-MSAC- Assessment-Report.pdf [verified July 2010].
12. Drummond MF, Sculpher MJ, Torrance GW, OBrien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
13. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137-150 doi:10.1093/ aje/kwm086
14. van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007; 165: 762-775 doi:10.1093/aje/kwk059 (Pubitemid 46434599)
15. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5: 11. doi:10.1186/1478-7954-5-11 (Pubitemid 351167796)
16. McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984; 64: 451-458
17. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol 2008; 9: 425-34. doi:10.1016/S1470-2045 (08)70103-70107
18. Howard K, Salkeld G, McCaffery K, Irwig L. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ 2008; 17: 593-605. doi:10.1002/hec.1278 (Pubitemid 351772340)
19. Dickinson JA. Cervical screening: time to change the policy. Med J Aust 2002; 176: 547-550
20. IARC Working Group on the Evaluation of Cancer. IARC handbooks of cancer prevention volume10: cervix cancer screening (10th edition). Lyon: IARC Press; 2005.
21. IARC. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. BMJ 1986; 293: 659-664 doi:10.1136/bmj.293. 6548.659
22. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89: 88-93. doi:10.1038/sj.bjc.6600974 (Pubitemid 36897941)
23. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339: b2968. doi:10.1136/bmj.b2968
24. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101 doi:10.1002/ijc.21955 (Pubitemid 44116919)
25. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26(Suppl. 10): K29-K41. doi:10.1016/ j.vaccine.2008.06.019
26. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004; 91: 530-536 doi:10.1038/sj.bjc. 6602002
27. Australian Bureau of Statistics (ABS). NationalHealth Survey, summary of results, Australia, 2004-2005. Cat. No.4364.0. Canberra: ABS; 2006.
28. Medical Services Advisory Committee. Completed assessments. 4-11-2010. Canberra: MSAC. Available online at: . gov.au/internet/msac/publishing.nsf/ content/app1122-1 [accessed February 2010].
29. NPAAC. Performance measures for Australian laboratories reporting cervical cytology. Canberra: Department of Health and Ageing, National Pathology Accreditation Advisory Council; 2006.
30. Williams AR. Liquid-based cytology and conventional smears compared over two 12-month periods. Cytopathology 2006; 17: 82-85 doi:10.1111/j.1365-2303. 2006.00339.x
31. Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010; 102: 933-939 doi:10.1038/sj.bjc. 6605528
32. Brotherton J, Deeks S, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008; 32: 457-461
33. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927 doi:10.1056/NEJMoa061741 (Pubitemid 46740302)
34. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-753 doi:10.1001/jama. 298.7.743
35. Riethmuller D, for the Quadrivalent HPV Vaccine Investigators. Quadrivalent HPV 6/11/16/18 vaccine efficacy against persistent infection or disease in subjects with prior HPV vaccine HPV type infection. Abstract presented at EUROGIN (SS 3-6). EUROGIN 2010 Meeting, Monte Carlo, Monaco 17-20 February 2010.
36. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008; 123: 1854-1863 doi:10.1002/ijc. 23633
37. Anderson RM, Garnett GP. Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis 2000; 27: 636-643 doi:10.1097/00007435-200011000-00012
38. Garnett GP. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 2002; 78: 7-12. doi:10.1136/sti.78.1.7 (Pubitemid 34206306)
39. Regan DG, Philp DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 2007; 4: 147-163 doi:10.1071/SH07042 (Pubitemid 47339644)
40. Garland SM, Brotherton J. The prevalence of human papillomavirus infection in Australia: analysis of data from the Women, Human Papillomavirus prevalence, Indigenous, Non-Indigenous, Urban, Rural (WHINURS) study. Proceedings of the 24th International Papillomavirus Society Conference, Beijing, China; 2007 Nov 9.
41. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111: 145-153 doi:10.1002/cncr. 22751 (Pubitemid 46982691)
42. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588 doi:10.1056/NEJMoa071430 (Pubitemid 47598400)
43. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-1772 doi:10.1016/S0140-6736(07)61450-0 (Pubitemid 350137476)
44. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-1597 doi:10.1056/ NEJMoa073204
45. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-1876 doi:10.1016/S0140- 6736(03)14955-0 (Pubitemid 37518501)
46. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, Del MA, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-257 doi:10.1016/S1470-2045(09)70360-2
47. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol 2009; 10: 672-82. doi:10.1016/S1470- 2045(09)70156-70161
48. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) esting in primary cervical screening. Health Technol Assess 2009; 13: 1-150; iii-iv
49. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151: 1158-1171
50. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907. doi:10.1016/S0140-6736(07)61416-0 (Pubitemid 47371147)
51. Eder PS, Lou J, Huff J, Macioszek J. The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform. J Clin Virol 2009; 45: S85-92. doi:10.1016/S1386-6532(09)70013-7
52. Coutlee F, Mayrand MH, Roger M, Franco EL. Detection and typing of human papillomavirus nucleic acids in biological fluids. Public Health Genom 2009; 12: 308-318 doi:10.1159/000214921
53. Day SP, Hudson A, Mast A, Sander T, Curtis M, Olson S, et al. Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study. J Clin Virol 2009; 45: S63-72. doi:10.1016/S1386- 6532(09)70010-1
54. Kurtycz DF, Smith M, He R, Miyazaki K, Shalkham J. Comparison of methods trial for high-risk HPV. Diagn Cytopathol 2010; 38: 104-108
55. Thai H, Rangwala S, Gay T, Keating K, McLeod S, Nazarenko I, et al. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology. J Clin Virol 2009; 45(Suppl. 1): S93-7. doi:10.1016/ S1386-6532(09)70014-70019
56. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009; 35: 210-220 doi:10.1016/ j.ctrv.2008.10.005
57. Koukari A. Renewal of the National Cervical Screening Program. Talk at Preventing Cervical Cancer 2009, Melbourne, March, 2009.